Financials
Financial year 2025
NOVIL'PHARMA from Fernelmont, company number BE0870124840, closed financial year 2025 with a result of € 130,188 after tax. For that financial year NOVIL'PHARMA recorded a gross margin of € 304,100 and equity of € 744,411. Compared with financial year 2024, the result moved from € 87,835 to € 130,188. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.
€ 744,411
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 130,188
▲ 48% vs 2024
Profit after tax over the fiscal year.
€ 263,773
▼ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 87,000 paid out
67 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0.8
Average over the fiscal year, from the social balance sheet.
€ 41,489
▲ 6% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 19,857
▼ 31% vs 2024
Of which on lease € 2,613.
Debts at end 2025
€ 12,124
▼ 61% vs 2024
€ 10,752 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.
€ 37,427
▼ 67% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 44,447
▲ 31% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 265,439 | € 290,594 | € 297,604 | € 304,100 | ▲ 2% |
| Profit after taxes | € 107,722 | € 125,343 | € 87,835 | € 130,188 | ▲ 48% |
| Equity | € 588,544 | € 653,888 | € 702,723 | € 744,411 | ▲ 6% |
| Total debts | € 316,260 | € 299,474 | € 233,693 | € 163,555 | ▼ 30% |
| Cash | € 234,778 | € 96,266 | € 293,130 | € 263,773 | ▼ 10% |
| Land & buildings | € 94,464 | € 112,996 | € 107,317 | € 101,637 | ▼ 5% |
| Retained profit | € 569,944 | € 635,288 | € 684,123 | € 725,811 | ▲ 6% |
| Dividend | € 28,000 | € 60,000 | € 39,000 | € 87,000 | ▲ 123% |
| Bank debt | € 77,410 | € 64,911 | € 30,715 | € 12,124 | ▼ 61% |
| Balance sheet total | € 904,804 | € 953,361 | € 982,326 | € 907,966 | ▼ 8% |
| Employees (FTE) | 0.8 | - | 0.8 | 0.8 |
Key figures of NOVIL'PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NOVIL'PHARMA?
What happened at NOVIL'PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 130,188 (▲ 48% vs 2024). filed late Source: NBB ↗
- New establishment in Fernelmont. KBO
- Start of the company according to the CBE. KBO
In short
From € 107,722 profit in 2022 to € 130,188 profit in 2025.
Paid € 251,760 in corporate taxes since 2022.
Best year ever: 2025, with € 130,188 profit.
Paid out € 214,000 in dividends to the owners in total.
A new publication or filing at NOVIL'PHARMA? We notify you, reason included.
Follow NOVIL'PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind NOVIL'PHARMA are Verborg Sabine and Poncelet Caroline.
Directors
According to the 2025 annual accounts
Verborg Sabine
Director
Poncelet Caroline
Director
Establishments
Establishment units
Physical locations of this company
Rue de la Victoire, Nov. 6
5380 Fernelmont
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0870.124.840
- VAT number
- BE 0870.124.840
- Registered office
- Rue de la Victoire, Nov. 6, 5380 Fernelmont
- Names & denominations
- NOVIL'PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 November 2004
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers